RU2100366C1 - Антрациклиновые гликозиды и их фармацевтически приемлемые кислотно-аддитивные соли, способ их получения, дииодопромежуточное соединение и способ его получения - Google Patents
Антрациклиновые гликозиды и их фармацевтически приемлемые кислотно-аддитивные соли, способ их получения, дииодопромежуточное соединение и способ его получения Download PDFInfo
- Publication number
- RU2100366C1 RU2100366C1 SU915001540A SU5001540A RU2100366C1 RU 2100366 C1 RU2100366 C1 RU 2100366C1 SU 915001540 A SU915001540 A SU 915001540A SU 5001540 A SU5001540 A SU 5001540A RU 2100366 C1 RU2100366 C1 RU 2100366C1
- Authority
- RU
- Russia
- Prior art keywords
- doxorubicin
- morpholinyl
- compound
- hydrochloride
- desamino
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 title claims abstract description 27
- 229940045799 anthracyclines and related substance Drugs 0.000 title claims abstract description 19
- 229930182470 glycoside Natural products 0.000 title claims abstract description 16
- 150000002338 glycosides Chemical class 0.000 title claims abstract description 16
- 150000003839 salts Chemical class 0.000 title claims description 14
- 230000015572 biosynthetic process Effects 0.000 title abstract 3
- 238000003786 synthesis reaction Methods 0.000 title abstract 3
- 239000000654 additive Substances 0.000 title 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims abstract description 39
- 229960004679 doxorubicin Drugs 0.000 claims abstract description 34
- 230000002829 reductive effect Effects 0.000 claims abstract description 10
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 8
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical class N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 claims abstract description 5
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000006277 sulfonation reaction Methods 0.000 claims abstract description 4
- 230000026045 iodination Effects 0.000 claims abstract description 3
- 238000006192 iodination reaction Methods 0.000 claims abstract description 3
- 230000003647 oxidation Effects 0.000 claims abstract description 3
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract 4
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims abstract 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 7
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims description 6
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 claims description 3
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 claims description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 3
- 150000007530 organic bases Chemical class 0.000 claims description 3
- 239000003880 polar aprotic solvent Substances 0.000 claims description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 2
- 230000000737 periodic effect Effects 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims 2
- SXCIMUIAZXOVIR-PUCKCBAPSA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1 SXCIMUIAZXOVIR-PUCKCBAPSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229940126214 compound 3 Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 2
- 230000003993 interaction Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 65
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- 239000002904 solvent Substances 0.000 description 27
- 238000004809 thin layer chromatography Methods 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 5
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 229940126062 Compound A Drugs 0.000 description 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 4
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- YWAIDTJFALVPHL-YFKPBYRVSA-N (1s)-2-iodo-1-(2-iodoethoxy)-1-methoxyethane Chemical compound CO[C@H](CI)OCCI YWAIDTJFALVPHL-YFKPBYRVSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- YWAIDTJFALVPHL-RXMQYKEDSA-N (1r)-2-iodo-1-(2-iodoethoxy)-1-methoxyethane Chemical compound CO[C@@H](CI)OCCI YWAIDTJFALVPHL-RXMQYKEDSA-N 0.000 description 2
- PADZQGJLBROXLI-YFKPBYRVSA-N (2s)-2-(2-hydroxyethoxy)-2-methoxyethanol Chemical compound CO[C@H](CO)OCCO PADZQGJLBROXLI-YFKPBYRVSA-N 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- XOFIBYLQFDNQQG-LJQANCHMSA-N 2-[(1r)-1-methoxy-2-(4-methylphenyl)sulfonyloxyethoxy]ethyl 4-methylbenzenesulfonate Chemical compound C([C@H](OC)OCCOS(=O)(=O)C=1C=CC(C)=CC=1)OS(=O)(=O)C1=CC=C(C)C=C1 XOFIBYLQFDNQQG-LJQANCHMSA-N 0.000 description 2
- XOFIBYLQFDNQQG-IBGZPJMESA-N 2-[(1s)-1-methoxy-2-(4-methylphenyl)sulfonyloxyethoxy]ethyl 4-methylbenzenesulfonate Chemical compound C([C@@H](OC)OCCOS(=O)(=O)C=1C=CC(C)=CC=1)OS(=O)(=O)C1=CC=C(C)C=C1 XOFIBYLQFDNQQG-IBGZPJMESA-N 0.000 description 2
- ALEDGHAEHAUNTA-RUZDIDTESA-N 2-[(1s)-2-(4-methylphenyl)sulfonyloxy-1-phenylmethoxyethoxy]ethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCO[C@H](OCC=1C=CC=CC=1)COS(=O)(=O)C1=CC=C(C)C=C1 ALEDGHAEHAUNTA-RUZDIDTESA-N 0.000 description 2
- NFGJXFFDMVOUCD-LLVKDONJSA-N [(1s)-2-iodo-1-(2-iodoethoxy)ethoxy]methylbenzene Chemical compound ICCO[C@@H](CI)OCC1=CC=CC=C1 NFGJXFFDMVOUCD-LLVKDONJSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Inorganic materials [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- PADZQGJLBROXLI-RXMQYKEDSA-N (2r)-2-(2-hydroxyethoxy)-2-methoxyethanol Chemical compound CO[C@@H](CO)OCCO PADZQGJLBROXLI-RXMQYKEDSA-N 0.000 description 1
- OIYPNUBAMNZWAB-SSDOTTSWSA-N (2r)-2-(2-hydroxyethoxy)-2-propan-2-yloxyethanol Chemical compound CC(C)O[C@H](CO)OCCO OIYPNUBAMNZWAB-SSDOTTSWSA-N 0.000 description 1
- CUOMYDZNJOUCKP-RXMQYKEDSA-N (2r)-2-methoxy-2-(2-oxoethoxy)acetaldehyde Chemical compound CO[C@@H](C=O)OCC=O CUOMYDZNJOUCKP-RXMQYKEDSA-N 0.000 description 1
- WZOMEFALYDMUDO-LLVKDONJSA-N (2s)-2-(2-hydroxyethoxy)-2-phenylmethoxyethanol Chemical compound OCCO[C@@H](CO)OCC1=CC=CC=C1 WZOMEFALYDMUDO-LLVKDONJSA-N 0.000 description 1
- KNHULHZQUWNEQF-LURJTMIESA-N (2s)-2-ethoxy-2-(2-hydroxyethoxy)ethanol Chemical compound CCO[C@H](CO)OCCO KNHULHZQUWNEQF-LURJTMIESA-N 0.000 description 1
- CUOMYDZNJOUCKP-YFKPBYRVSA-N (2s)-2-methoxy-2-(2-oxoethoxy)acetaldehyde Chemical compound CO[C@H](C=O)OCC=O CUOMYDZNJOUCKP-YFKPBYRVSA-N 0.000 description 1
- 0 *C(C(C1)C1C(C(C1)O)=N)C1O Chemical compound *C(C(C1)C1C(C(C1)O)=N)C1O 0.000 description 1
- BCVJOHKWNDSWKX-OAQYLSRUSA-N 2-[(1r)-2-(4-methylphenyl)sulfonyloxy-1-propan-2-yloxyethoxy]ethyl 4-methylbenzenesulfonate Chemical compound C([C@@H](OC(C)C)OCCOS(=O)(=O)C=1C=CC(C)=CC=1)OS(=O)(=O)C1=CC=C(C)C=C1 BCVJOHKWNDSWKX-OAQYLSRUSA-N 0.000 description 1
- YEZXEWXONCOWQT-SSDOTTSWSA-N 2-[(1r)-2-iodo-1-(2-iodoethoxy)ethoxy]propane Chemical compound CC(C)O[C@H](CI)OCCI YEZXEWXONCOWQT-SSDOTTSWSA-N 0.000 description 1
- LFSFHTZBPADHSO-FQEVSTJZSA-N 2-[(1s)-1-ethoxy-2-(4-methylphenyl)sulfonyloxyethoxy]ethyl 4-methylbenzenesulfonate Chemical compound C([C@@H](OCC)OCCOS(=O)(=O)C=1C=CC(C)=CC=1)OS(=O)(=O)C1=CC=C(C)C=C1 LFSFHTZBPADHSO-FQEVSTJZSA-N 0.000 description 1
- ZWNQOGXZYOIMLT-UHFFFAOYSA-N 2-ethoxyethoxymethylbenzene Chemical compound CCOCCOCC1=CC=CC=C1 ZWNQOGXZYOIMLT-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- AYJRCSIUFZENHW-DEQYMQKBSA-L barium(2+);oxomethanediolate Chemical compound [Ba+2].[O-][14C]([O-])=O AYJRCSIUFZENHW-DEQYMQKBSA-L 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- ZIQRIAYNHAKDDU-UHFFFAOYSA-N sodium;hydroiodide Chemical compound [Na].I ZIQRIAYNHAKDDU-UHFFFAOYSA-N 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/30—Compounds having groups
- C07C43/313—Compounds having groups containing halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB898928654A GB8928654D0 (en) | 1989-12-19 | 1989-12-19 | Preparation of 2-methoxy-4-morpholinyl anthracyclines |
| GB909007513A GB9007513D0 (en) | 1990-04-03 | 1990-04-03 | Morpholinyl derivatives of doxorubicin and process for their preparation |
| PCT/EP1990/002229 WO1991009046A1 (en) | 1989-12-19 | 1990-12-18 | Morpholinyl derivatives of doxorubicin and process for their preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2100366C1 true RU2100366C1 (ru) | 1997-12-27 |
Family
ID=26296395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU915001540A RU2100366C1 (ru) | 1989-12-19 | 1990-12-18 | Антрациклиновые гликозиды и их фармацевтически приемлемые кислотно-аддитивные соли, способ их получения, дииодопромежуточное соединение и способ его получения |
Country Status (28)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2563638C2 (ru) * | 2010-12-02 | 2015-09-20 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Способ получения производных морфолинилантрациклина |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5843903A (en) * | 1995-11-27 | 1998-12-01 | The Administrators Of The Tulane Educational Fund | Targeted cytotoxic anthracycline analogs |
| NZ518764A (en) * | 1999-12-29 | 2004-02-27 | Immunogen Inc | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| NZ575452A (en) | 2002-05-24 | 2010-03-26 | Angiotech Int Ag | Compositions and methods for coating medical implants such as vascular grafts, catheters, pacemakers etc |
| ATE416795T1 (de) | 2002-09-26 | 2008-12-15 | Angiotech Int Ag | Perivaskuläre hüllen |
| DE60331367D1 (de) | 2002-12-30 | 2010-04-01 | Angiotech Int Ag | Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung |
| WO2004082689A1 (en) * | 2003-03-18 | 2004-09-30 | Pharmacia Italia Spa | Combined therapy comprising nemorubicin and a cyclooxygenase-2-inhibitor |
| EP2049530A2 (en) * | 2006-07-12 | 2009-04-22 | Nerviano Medical Sciences S.r.l. | Crystalline nemorubicin hydrochloride |
| US9115165B2 (en) * | 2008-04-11 | 2015-08-25 | Tianjin Hemay Bio-Tech Co., Ltd. | Tetracyclic anthraquinone antibiotic derivatives with high activity, process for preparing the same and use thereof |
| CN101353361B (zh) * | 2008-08-08 | 2011-06-01 | 中国人民解放军第四军医大学 | 一种阿霉素前体药物的制备方法及其应用 |
| CN105164138B (zh) | 2013-04-29 | 2017-11-07 | 内尔维阿诺医学科学有限公司 | 新吗啉基蒽环类抗生素衍生物 |
| JP2017502950A (ja) | 2013-12-11 | 2017-01-26 | ユニバーシティー オブ マサチューセッツＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ | サルモネラＴ３ＳＳエフェクタータンパク質（ＳｉｐＡ）を使用した疾患を治療するための組成物および方法 |
| JP6785780B2 (ja) | 2014-11-05 | 2020-11-18 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 官能基化モルホリニルアントラサイクリン誘導体 |
| CN115043895A (zh) * | 2022-07-15 | 2022-09-13 | 戊言医药科技（上海）有限公司 | 一种pnu-159682及其中间体的制备方法 |
| CN119997985A (zh) * | 2022-08-15 | 2025-05-13 | 西纳福克斯股份有限公司 | 蒽环类药物及其缀合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2883443A (en) * | 1956-07-13 | 1959-04-21 | Ruetschi Karl | Lead-acid storage battery |
| US4423123A (en) * | 1980-04-17 | 1983-12-27 | Shin-Kobe Electric Machinery Co., Ltd. | Electric storage battery and a method of making the same |
| JPS57163393A (en) * | 1981-03-27 | 1982-10-07 | Microbial Chem Res Found | Novel anthracyclin derivative and its preparation |
| US4363857A (en) * | 1981-10-16 | 1982-12-14 | General Motors Corporation | Laminated metal-plastic battery grid |
| US4710564A (en) * | 1985-01-18 | 1987-12-01 | Microbial Chemistry Research Foundation | Anthracycline compounds |
| GB2172594B (en) * | 1985-03-22 | 1988-06-08 | Erba Farmitalia | New morpholino derivatives of daunorubicin and doxorubicin |
| JPS6215323A (ja) * | 1986-02-14 | 1987-01-23 | Dainippon Ink & Chem Inc | 微多孔中空繊維の製造法 |
| US4861836A (en) * | 1986-12-23 | 1989-08-29 | Daikin Industries Ltd. | Novel, iodine-containing compound, preparation thereof and block copolymer comprising the same |
-
1990
- 1990-11-15 EP EP90121905A patent/EP0434960B1/en not_active Expired - Lifetime
- 1990-11-15 ES ES90121905T patent/ES2094136T3/es not_active Expired - Lifetime
- 1990-11-15 DK DK90121905.5T patent/DK0434960T3/da active
- 1990-11-15 DE DE69028610T patent/DE69028610T2/de not_active Expired - Fee Related
- 1990-11-15 AT AT90121905T patent/ATE143023T1/de not_active IP Right Cessation
- 1990-12-12 IL IL9664390A patent/IL96643A/en not_active IP Right Cessation
- 1990-12-12 NZ NZ243695A patent/NZ243695A/xx unknown
- 1990-12-12 IL IL111527A patent/IL111527A/en not_active IP Right Cessation
- 1990-12-12 SK SK6219-90A patent/SK278994B6/sk unknown
- 1990-12-12 CZ CS906219A patent/CZ281949B6/cs not_active IP Right Cessation
- 1990-12-14 TW TW079110518A patent/TW208019B/zh active
- 1990-12-17 SI SI9012379A patent/SI9012379B/sl not_active IP Right Cessation
- 1990-12-17 YU YU237990A patent/YU48136B/sh unknown
- 1990-12-17 MY MYPI94001426A patent/MY119192A/en unknown
- 1990-12-17 IE IE454390A patent/IE81174B1/en not_active IP Right Cessation
- 1990-12-17 PT PT96226A patent/PT96226B/pt not_active IP Right Cessation
- 1990-12-18 RU SU915001540A patent/RU2100366C1/ru not_active IP Right Cessation
- 1990-12-18 WO PCT/EP1990/002229 patent/WO1991009046A1/en not_active Ceased
- 1990-12-18 CN CN90110144A patent/CN1024922C/zh not_active Expired - Fee Related
- 1990-12-18 AU AU69194/91A patent/AU636429B2/en not_active Ceased
- 1990-12-18 HU HU912994A patent/HU208148B/hu not_active IP Right Cessation
- 1990-12-18 UA UA5001540A patent/UA27108A1/uk unknown
- 1990-12-18 JP JP50124491A patent/JP3300342B2/ja not_active Expired - Fee Related
- 1990-12-18 KR KR1019910700930A patent/KR0183033B1/ko not_active Expired - Fee Related
- 1990-12-18 CA CA002046857A patent/CA2046857C/en not_active Expired - Fee Related
- 1990-12-18 HU HU9200656A patent/HU209433B/hu unknown
-
1991
- 1991-08-14 NO NO913176A patent/NO175533C/no unknown
- 1991-08-16 FI FI913887A patent/FI97389C/fi active
-
1992
- 1992-11-11 HR HRP-2379/90A patent/HRP921226B1/xx not_active IP Right Cessation
-
1993
- 1993-03-05 CN CN93102413A patent/CN1039708C/zh not_active Expired - Fee Related
-
1994
- 1994-03-09 NO NO940831A patent/NO176911C/no unknown
- 1994-11-04 IL IL11152794A patent/IL111527A0/xx unknown
-
1996
- 1996-11-06 GR GR960402934T patent/GR3021557T3/el unknown
Non-Patent Citations (1)
| Title |
|---|
| GB, патент, 2172594, кл. C 07 D 413/04, 1986. GB, патент, 2124224, кл. C 07 D 413/04, 1984. US, патент, 4672057, кл. A 61 K 31/70, 1986. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2563638C2 (ru) * | 2010-12-02 | 2015-09-20 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Способ получения производных морфолинилантрациклина |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2100366C1 (ru) | Антрациклиновые гликозиды и их фармацевтически приемлемые кислотно-аддитивные соли, способ их получения, дииодопромежуточное соединение и способ его получения | |
| US4672057A (en) | Morpholino derivatives of daunorubicin and doxorubicin | |
| US5304687A (en) | Morpholinyl derivatives of doxorubicin and process for their preparation | |
| US4366149A (en) | Antitumor anthracycline glycosides, their preparation, intermediates therefor, and compositions and use thereof | |
| BE1000158A4 (fr) | Nouveaux anthracycline glycosides, leur procede de preparation et leur application comme agents antitumoraux. | |
| FR2605321A1 (fr) | Anthracycline glycosides a activite antitumorale, leur preparation, les composes intermediaires de cette preparation et compositions et utilisation de ces substances. | |
| US4199571A (en) | Substituted anthracyclines, their preparation and use | |
| AU632102B2 (en) | New 3'-(4-morpholinyl)- and 3'-(2-methoxy-4-morpholinyl)- anthracycline derivatives | |
| JP3068258B2 (ja) | １３−ジヒドロ−３′−（２−アルコキシ−４−モルホリニル）アンスラサイクリン | |
| HU206700B (en) | Process for producing new 4'-epi-4'-amino-antracyclines and pharmaceutical compositions containing them | |
| BE1001688A5 (fr) | Nouveaux derives de demethoxy-4 anthracycline. | |
| EP0475071A1 (en) | 2-acyloxy-4-morpholinyl anthracycline | |
| US4604381A (en) | 4-demethoxy-13-dihydrodaunorubicin and use thereof | |
| EP0683787B1 (en) | 4'-o-sulfonyl-anthracycline derivatives | |
| KR20010013772A (ko) | 13-디하이드로-3' 아지리디노 안트라사이클린 | |
| JPS6260397B2 (cg-RX-API-DMAC7.html) | ||
| JPH01311095A (ja) | ４―デメトキシ―４′―デオキシ―４′―ヨードアントラサイクリングリコシド | |
| GB2159518A (en) | New anthracyclines and process for manufacture |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC4A | Invention patent assignment |
Effective date: 20071010 |
|
| RH4A | Copy of patent granted that was duplicated for the russian federation |
Effective date: 20071010 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20081219 |
|
| REG | Reference to a code of a succession state |
Ref country code: RU Ref legal event code: MM4A Effective date: 20081219 |